MedTrace Logo

Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM

NCT02289235 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-10-20

No results posted yet for this study

Summary

The investigators want to evaluate the effects and safety of ginger in treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

Ginger

Ginger powder capsule 1000 mg twice daily for 3 months

DRUG

Placebo

Placebo powder 2 capsules twice daily for 3 months

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mesbah Shams, M.D. · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

  • Majid Nimruzi, M.D. · Research Center for Traditional Medicine, Shiraz University of Medical Sciences

  • Kamran Bagheri Lankarani, M.D. · Health policy Research Center, Shiraz University of Medical Sciences

  • Parisa-sadaat Ghoreishi, M.D. · Shiraz University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-01-01
Completion
2020-02-01

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289235 on ClinicalTrials.gov